Third, we cannot exclude the possibility that the absence of a causal link between statins and MS severity is due to other pathways unrelated to Rho GTPases or HMGCR inhibition, which we could not investigate here because such pathways remain to be identified. This evidence concerns the gene HMGCR and myeloid sarcoma.